If Richard Padzur retires, he would become one of several high-ranking FDA officials who left the agency in 2025.

On 1 December, the fortunes of the UK pharma sector changed radically, with the UK Government becoming the first in the world ...

Citizen Health has entered a multi-year strategic partnership with UCB for expediting drug development across five rare ...

Patient advocacy and industry bodies welcomed the bill’s backing, though it will now need to be passed in the Senate.

The UK becomes the latest country in President Donald Trump’s long line of trade agreements, though it is the first region to ...

If approved, Regeneron and Tessera's TSRA-196 could become the first curative therapy to reach patients with AATD, who have ...

Biotechs in the charter city of Próspera aim to cure ageing, but experts question the feasibility of their goals.

New non-primate draft guidance follows the FDA's wider aim to curtail the use of animal testing in preclinical toxicology.

With $1.5 billion in drug sales, the US dominated the CKD-HPT, HP and HK market in 2024, representing 59.7% of 7MM sales.

Rare disease research faces complex regulations, small patient populations, and high costs. As traditional incentives wane, ...

As 2026 approaches, rising complexity, geopolitical pressures and new modalities are reshaping strategy, capacity and CDMO ...

Eisai has submitted a new drug application to Japan’s PMDA seeking approval for Leqembi’s SC formulation, SC-AI, for early ...